Spinal Decompression Therapy: Claims and Evidence

Non-surgical spinal decompression therapy is a modality of motorized traction intended to alleviate back pain by applying a distractive force to the spine, most commonly used in chiropractic and physical therapy settings for conditions like herniated or bulging discs, degenerative disc disease, and sciatica [^3]. The theoretical mechanism, proposed by Allan Dyer, MD, inventor of the VAX-D device, is the creation of negative intradiscal pressure, which is claimed to retract herniated disc material and promote a flow of healing nutrients to the disc [^1]. A 1994 study by Ramos and Martin appeared to support this by measuring intradiscal pressures dropping to between -100 and -160 mm Hg during treatment [^5]. This modality is situated within the broader chiropractic use of mechanical therapies and traction, which are established components of the profession's therapeutic toolkit ``.¹

The central controversy surrounding spinal decompression therapy involves the disparity between its marketing claims and the body of scientific evidence. Beginning in the 1990s, manufacturers and clinicians sought to distinguish this new generation of computerized tables from older forms of traction [^16]. Devices such as the DRX9000, which received FDA 510(k) clearance (K060735) as a Class II powered traction device, were marketed with claims of using proprietary technology, like a servo motor applying a "logarithmic curve" pull, to bypass the body's natural muscle guarding reflex [^2][^11]. This was purported to achieve the desired negative pressure more effectively than conventional traction. These claims were often paired with advertised success rates of 77% to 86% in non-randomized, uncontrolled studies and a high out-of-pocket cost for patients, often ranging from $2,000 to $5,000 for a course of treatment [^12][^14].

However, the clinical evidence supporting the superiority of these devices over less expensive alternatives is contested. A 2006 systematic review by Macario and Pergolizzi concluded that the efficacy of motorized traction for chronic discogenic low back pain remained "unproven," noting that the available literature consisted primarily of low-quality studies and that six of seven randomized trials showed no difference in outcomes compared to controls [^7][^12]. A 2009 randomized controlled trial by Schimmel et al. found no significant difference in outcomes at a one-year follow-up between patients receiving a form of decompression therapy and those receiving a sham treatment [^10]. Similarly, a 2017 trial by Demirel et al. found no statistically significant difference in outcomes between motorized decompression and conventional motorized traction groups [^13]. In a 2007 critical review, chiropractor Dwain M. Daniel concluded that only limited evidence was available to justify its routine use [^6]. Reflecting this uncertainty, the treatment is not mentioned in the 2020 evidence-based clinical guidelines for non-specific low back pain from the North American Spine Society (NASS) [^9]. This article will examine the claims, mechanisms, and evidence for non-surgical spinal decompression therapy, detailing the regulatory history of key devices, analyzing the results of major clinical trials, and discussing its current status within chiropractic and multidisciplinary spine care.

Historical development from traction to decompression

The use of traction, or the application of a longitudinal pulling force to the spine, has a long history in the management of low back pain. For decades, clinicians including chiropractors used various forms of mechanical traction with the goal of separating vertebral bodies, relieving nerve root compression, and reducing pain.² These traditional methods, detailed in chiropractic technique textbooks, often involved simple motorized pulley systems with static or intermittent forces.³ A significant limitation of conventional traction was its tendency to elicit a protective muscle guarding reflex, where paraspinal muscles contract in response to the pulling force, thereby increasing intradiscal pressure and potentially counteracting the therapeutic goal.

A significant shift occurred in the 1990s with the development of sophisticated, computer-controlled devices marketed under the new term "spinal decompression." This evolution was driven by both technological innovation and a deliberate marketing strategy to differentiate the new equipment from older, less effective forms of traction ⁴. The VAX-D (Vertebral Axial Decompression) device, introduced by its inventor Allan Dyer, MD, was a progenitor of this new category. Dyer proposed that the device worked by creating a significant negative intradiscal pressure, or a vacuum effect, which could retract herniated nuclear material and encourage nutrient flow to the disc ⁵. This theoretical mechanism received early support from a 1994 study by Ramos and Martin, which used invasive intradiscal pressure measurements in three subjects and reported pressure drops to between -100 and -160 mm Hg during treatment ⁶.

Following the VAX-D, a new generation of devices emerged in the 2000s, most notably the DRX9000. The marketing for these devices focused heavily on their purported ability to overcome the limitations of traditional traction. The DRX9000, for instance, claimed to use a proprietary servo motor to apply a tension force along a "logarithmic curve," a pull pattern asserted to be subtle enough to bypass the body's muscle guarding reflex and achieve the desired negative intradiscal pressure ⁷. This terminology helped position "decompression" as a high-technology, specific, and advanced intervention distinct from generic traction.

Despite these claims of a unique mechanism, the regulatory pathway for these devices did not require proof of superior efficacy. The Axiom DRX9000, for example, received its clearance from the U.S. Food and Drug Administration (FDA) through the 510(k) premarket notification process (K060735). This process classified it as a Class II powered traction device, establishing it as "substantially equivalent" to predicate devices already on the market rather than validating its novel mechanistic claims ⁸. The device's cleared indications for use included "relief of pain and symptoms associated with herniated discs, bulging/protruding discs, degenerative disc disease, posterior facet syndrome, and sciatica" ⁹. This regulatory status contrasted with marketing materials that often presented decompression as a revolutionary breakthrough. A 2006 systematic review by Macario and Pergolizzi highlighted this discrepancy, noting that advertised success rates of 77% to 86% were derived from non-randomized studies lacking control groups, whereas six of seven randomized studies they reviewed reported no difference in outcomes with motorized decompression ¹⁰. The review concluded that the therapy's efficacy remained "unproven" ¹¹.

Theories and claimed mechanisms of action

The central theory behind non-surgical spinal decompression is the generation of negative pressure within the intervertebral disc. This concept was primarily advanced by Allan Dyer, MD, the inventor of the VAX-D device. Dyer proposed that by applying a specific, controlled distraction force to the spine, a subatmospheric or negative intradiscal pressure could be created. This "vacuum effect" is theorized to draw in or retract herniated or bulging disc material, pulling it back from nerve roots and into the disc space. The negative pressure is also claimed to promote the diffusion of water, oxygen, and nutrients into the disc, thereby facilitating healing of degenerative or damaged tissue ⁵.

Evidence supporting the creation of negative pressure was provided in a 1994 study by G. Ramos and W. Martin. In their experiment, they measured intradiscal pressure in the third lumbar disc of subjects undergoing treatment. They reported that the pressure decreased significantly during the application of vertebral axial decompression, reaching values between -100 and -160 mm Hg ⁶. This finding has been widely cited by manufacturers and clinicians as direct proof of the therapy's primary mechanism. While the principles of applying traction to the spine are a long-standing component of physical medicine and chiropractic technique, modern decompression devices claim to be distinct from conventional traction.¹²

Manufacturers of devices like the Axiom DRX9000, which was cleared by the FDA as a Class II powered traction device ⁸, assert that their technology incorporates advanced features to overcome a key limitation of older traction methods. The primary claim is that these computerized systems can bypass the body's proprioceptive response, specifically the paravertebral muscle guarding reflex ⁷⁴. This reflex is an involuntary muscle contraction that occurs when the spine is stretched, which can increase intradiscal pressure and potentially counteract the intended decompressive effect. The DRX9000 claims to achieve this by using a servo motor to apply the distraction force in a precise, "logarithmic curve" pull pattern. This computer-controlled, oscillating pull-and-relax cycle is purported to be subtle enough to avoid triggering the muscle guarding reflex, thus allowing for a more profound and effective decompression of the disc ⁷.

This claimed ability to bypass muscle guarding was a central element in marketing efforts during the 1990s and 2000s, positioning the therapy as a high-tech evolution of traditional traction ⁴. However, the clinical superiority of this proposed mechanism has been challenged. For instance, a 2009 randomized controlled trial by Schimmel et al. compared a form of motorized decompression (IDD Therapy) against a sham traction treatment and found no significant difference in outcomes at the one-year follow-up ¹³. Such findings raise questions about whether the sophisticated mechanisms claimed by manufacturers translate into measurably better clinical results than placebo or simpler forms of traction. A 2007 critical review by Dwain M. Daniel, DC, further concluded that there was limited evidence to warrant the routine use of the therapy, given the existence of other well-researched and less expensive alternatives ¹⁴.

Regulatory status and marketing practices

The market entry and promotion of non-surgical spinal decompression devices are heavily influenced by the U.S. Food and Drug Administration's (FDA) regulatory framework. Devices such as the Axiom DRX9000 gained market access through the FDA's 510(k) premarket notification pathway ⁸. This process, under which the DRX9000 was cleared with number K060735, classifies the device as a Class II powered traction device ⁸. The 510(k) clearance does not require manufacturers to submit new clinical trial data proving the device's efficacy. Instead, it requires a demonstration of "substantial equivalence" to a legally marketed predicate device. Consequently, the DRX9000 was cleared for indications including the "relief of pain and symptoms associated with herniated discs, bulging/protruding discs, degenerative disc disease, posterior facet syndrome, and sciatica," without having to provide original evidence that it was superior to existing forms of traction or a placebo ⁹.

This regulatory pathway has shaped the marketing strategies employed by manufacturers and clinicians. Lacking a mandate to prove superior efficacy through rigorous trials, marketing materials often rely on data from uncontrolled, non-randomized studies to promote high success rates. A 2006 systematic review by Macario and Pergolizzi highlighted this discrepancy. The review found that marketing for motorized decompression frequently advertised success rates between 77% and 86% ¹⁰. However, these figures were sourced from three non-randomized studies that lacked a control group for comparison. In contrast, the same review analyzed seven randomized studies and found that six of them reported no significant difference in patient outcomes when motorized decompression was compared to other interventions ¹⁰.

A central theme in marketing has been to differentiate these computerized devices from conventional traction, which has a long history and is considered by some to be less effective. This strategy, prominent since the 1990s, posited that new devices could bypass the body's protective muscle-guarding reflex, a claim not substantiated by high-quality evidence ⁴. For example, the DRX9000 is marketed with the claim that its servo motor applies a specific "logarithmic curve" pull pattern designed to prevent the paraspinal muscle contraction that can limit the effectiveness of traditional traction ⁷. This narrative of technological sophistication, combined with the promotion of impressive success rates from lower-quality studies, has been a key component of the promotional efforts directed at both clinicians and patients. The significant out-of-pocket cost for patients, often between $2,000 and $5,000 for a course of treatment, further underscores the commercial incentive to present the therapy as a uniquely effective, high-technology solution ¹⁵.

Evidence from systematic reviews and critical analyses

The evaluation of motorized spinal decompression at the highest levels of evidence, namely systematic reviews and critical analyses, has consistently highlighted a significant gap between marketing claims and scientific validation. A 2006 systematic review by Antonio Macario and Joseph Pergolizzi, Jr. for Pain Practice examined the literature for motorized traction in chronic discogenic low back pain and concluded that its efficacy remained "unproven" ¹¹. The authors attributed this finding to the literature consisting of a small number of low-quality studies ¹¹. Their analysis further revealed a stark contrast between the findings of randomized and non-randomized research. While three non-randomized studies lacking control groups reported advertised success rates between 77% and 86%, six of the seven randomized controlled trials (RCTs) reviewed found no significant difference in outcomes between motorized decompression and other interventions ¹⁰.

This conclusion was echoed in a 2007 critical review by Dwain M. Daniel, DC, who asserted that "Only limited evidence is available to warrant the routine use of non-surgical spinal decompression" ¹⁴. Daniel emphasized that this was particularly true when considering the availability of many other "well investigated, less expensive alternatives" ¹⁴. The distinction between newer, computerized forms of traction and older methods remains a subject of debate within the chiropractic profession, with textbooks on technique outlining the principles and application of various traction forms.

Specific high-quality clinical trials have reinforced the conclusions of these reviews. A 2009 randomized controlled trial by Schimmel et al. published in the European Spine Journal investigated Intervertebral Differential Dynamics (IDD) therapy, a form of motorized decompression. The study found no significant difference in outcomes at the one-year follow-up point for patients receiving high-dose motorized traction plus standard physiotherapy compared to those who received a sham traction treatment plus the same physiotherapy ¹³. The lack of a superior effect over a placebo intervention directly challenges the proposed unique mechanisms of action, such as bypassing muscle guarding to create significant negative intradiscal pressure ⁵⁷.

More recent research has not substantially altered this evidence landscape. A 2017 randomized trial by Demirel et al. compared motorized decompression, conventional traction, and a control group, with all groups also receiving a standard physiotherapy program. The study found that while both traction modalities were more effective than physiotherapy alone, there was no statistically significant difference in overall outcomes between the spinal decompression and conventional motorized traction groups ¹⁶. A 2015 randomized controlled trial by Choi et al. comparing spinal decompression therapy to general traction therapy for intervertebral disc herniation found that while both groups showed statistically significant decreases in pain and Oswestry Disability Index scores, there were no statistically significant differences in the outcomes between the two groups. ¹⁷. Underscoring its status outside the mainstream of evidence-based care, the 2020 evidence-based clinical guidelines for multidisciplinary spine care from the North American Spine Society (NASS) do not include any recommendation for or against motorized spinal decompression, as the treatment is not mentioned ¹⁸.

Key randomized controlled trials

The specific claims made for motorized spinal decompression, such as the ability to bypass the body's protective muscle-guarding reflex, have necessitated evaluation through high-quality randomized controlled trials (RCTs) ⁴. These trials are designed to determine if the proposed unique mechanisms translate into superior clinical outcomes compared to either a placebo (sham) treatment or existing, less expensive therapies. The results of these key trials have been central to the ongoing debate about the therapy's value and place in evidence-based care.

A significant study directly testing the efficacy of decompression against a placebo was a 2009 randomized controlled trial conducted by Schimmel et al. In this trial, patients with chronic low back pain were assigned to one of two groups: one received high-dose motorized traction using Intervertebral Differential Dynamics (IDD) therapy along with standard physiotherapy, while the control group received a sham traction treatment plus the same physiotherapy. At the one-year follow-up, the researchers found no statistically significant difference in pain, disability, or other key outcomes between the patients who received the genuine decompression therapy and those who received the sham treatment ¹³. This finding suggests that the specific, complex pull patterns and purported physiological effects of the decompression device did not produce a better long-term result than a placebo when combined with standard physical therapy ¹⁹.

This result from a rigorous, sham-controlled trial echoes the conclusions of earlier systematic reviews. A 2006 review by Macario and Pergolizzi which analyzed the evidence for motorized traction for chronic discogenic low back pain, concluded that its efficacy remained "unproven" ¹¹. The review highlighted a critical divide in the available evidence: while non-randomized studies lacking a control group often advertised high success rates, six of the seven randomized studies included in their analysis found no significant difference in outcomes when motorized decompression was compared to a control or other treatment ¹⁰. This discrepancy underscores the importance of controlled trials in parsing therapeutic effects from placebo effects and the natural history of the condition.

The consistent failure of high-quality RCTs to demonstrate a clear, unique benefit has led to critical assessments from within the chiropractic and medical communities. A 2007 critical review authored by Dwain M. Daniel, DC, summarized the state of the evidence by concluding that "Only limited evidence is available to warrant the routine use of non-surgical spinal decompression, particularly when many other well investigated, less expensive alternatives are available" ¹⁴. While early, small-scale studies did measure physiological changes like decreased intradiscal pressure during treatment, the larger body of evidence from RCTs has largely failed to show that this mechanism translates into clinically superior results compared to sham or conventional traction ⁶.

Observational studies and proponent-cited evidence

Much of the evidence presented in patient-facing marketing materials and on practitioner websites consists of lower-level observational studies, such as case series and retrospective cohort studies. This body of literature, often funded or conducted by device manufacturers and proponents, reports high success rates but is methodologically limited. A central claim is that modern, computer-controlled devices are distinct from conventional traction because they can bypass the body's protective muscle guarding reflex ⁴. For instance, the DRX9000 device is marketed with the claim that it uses a servo motor to apply a "logarithmic curve" pull pattern to achieve this goal ⁷. The theoretical underpinning, first proposed by Allan Dyer, MD, inventor of the VAX-D device, is that this sophisticated pull creates a negative intradiscal pressure, or vacuum effect, which helps retract herniated disc material and promote healing ⁵.

Early research provided some physiological plausibility for this mechanism. A 1994 study by Ramos and Martin, often cited in promotional literature, used invasive needles to measure intradiscal pressure in the third lumbar disc during treatment. They reported that the pressure decreased to between -100 and -160 mm Hg during the application of vertebral axial decompression ⁶. Building on this, proponents point to clinical outcome studies that report significant patient improvement. A notable example is a 2010 retrospective cohort study by Apfel et al. on patients treated with the DRX9000. This study found that patients' mean Oswestry Disability Index (ODI) scores improved significantly from their baseline levels after a course of treatment ²⁰.

However, the evidentiary value of such studies is contested by systematic reviewers. The retrospective design of the Apfel study, for example, lacked a concurrent control group, making it impossible to distinguish the effects of the therapy from the placebo effect, the natural history of low back pain, or the effect of other concurrent treatments ²⁰. A 2006 systematic review by Macario and Pergolizzi analyzed the literature for motorized traction and found that its efficacy remained "unproven" ¹¹. The review highlighted a stark contrast between different study types: while three non-randomized studies without control groups advertised success rates of 77% to 86%, six of seven randomized studies found no significant difference in outcomes when compared to other treatments or sham decompression ¹⁰. Despite these critiques, devices like the Axiom DRX9000 received FDA 510(k) clearance (K060735) as a Class II powered traction device, a classification which demonstrates substantial equivalence to a legally marketed device but does not require proof of efficacy ⁸. This clearance, with an indication for use in relieving pain from conditions like herniated discs and sciatica, is frequently featured in marketing, often without clarification of the regulatory standard it represents ⁹. The promotion of this therapy, based on observational data, has led to treatment protocols that can cost patients $2,000 to $5,000 out-of-pocket ¹⁵.

Position in clinical guidelines and standard of care

The position of motorized spinal decompression within mainstream spine care is defined more by its absence from established protocols than by its inclusion. A key example is the 2020 edition of the North American Spine Society (NASS) evidence-based clinical guidelines for multidisciplinary spine care. These influential guidelines for non-specific low back pain do not mention motorized spinal decompression, either to recommend for or against its use, indicating that the therapy did not meet the evidentiary threshold for consideration by the guideline committee ¹⁸. This omission is significant, as it places the modality outside the standard of care recommended by one of the leading spine specialist organizations.

This lack of endorsement is consistent with conclusions from systematic reviews that often inform such guidelines. A 2006 review by Macario and Pergolizzi, examining motorized traction for chronic discogenic low back pain, concluded that its effectiveness remained "unproven" ¹¹. The authors noted a significant discrepancy in the literature: while three non-randomized studies without control groups reported high success rates, six of seven randomized studies they reviewed found no difference in outcomes between motorized decompression and control or sham treatments ¹⁰. A year later, a 2007 critical review authored by Dwain M. Daniel, DC, from within the chiropractic profession, concluded that only "limited evidence is available to warrant the routine use of non-surgical spinal decompression" and pointed to the existence of many "well investigated, less expensive alternatives" ¹⁴.

High-quality randomized controlled trials (RCTs) have further reinforced this skeptical view of the therapy's specific efficacy. A 2009 RCT by Schimmel et al. compared a form of decompression known as Intervertebral Differential Dynamics (IDD) therapy combined with standard physiotherapy against a sham traction treatment plus the same physiotherapy. The study found no significant difference in patient outcomes at the one-year follow-up point ¹³. While some research has shown benefits, the findings often fail to support the marketing claims that decompression is a technologically superior form of traction ⁴. For instance, a 2017 RCT by Demirel et al. found that adding either motorized decompression or conventional traction to a physiotherapy program was more effective than physiotherapy alone. However, the study also found no statistically significant difference in pain or disability outcomes between the group receiving spinal decompression and the group receiving conventional motorized traction ¹⁶.

This body of evidence, characterized by weak or unproven efficacy in systematic reviews and a failure to outperform sham treatments or conventional traction in RCTs ¹⁹¹⁶, explains the therapy's exclusion from major clinical practice guidelines. Despite the theoretical appeal of creating negative intradiscal pressure ⁶ and the FDA clearance of devices like the DRX9000 as Class II powered traction systems ⁸, motorized decompression has not been integrated into the standard of care for low back pain. It remains a modality used in private practice, often outside of insurance-based systems, and is typically presented as an adjunctive therapy within the broader category of mechanical traction in chiropractic textbooks such as Chiropractic Technique by Bergmann and Peterson.

Economic impact, debate, and limitations

A significant component of the debate surrounding motorized spinal decompression is its economic impact on patients, which contrasts sharply with the state of the scientific evidence. A typical course of treatment, such as 20 sessions on a DRX9000 device, is often quoted with an out-of-pocket cost ranging from $2,000 to $5,000, as the therapy is frequently not covered by insurance carriers ¹⁵. This substantial financial investment by patients creates a central conflict when viewed against the body of clinical research. In a 2007 critical review published in the Journal of Manipulative and Physiological Therapeutics, chiropractor Dwain M. Daniel concluded that "Only limited evidence is available to warrant the routine use of non-surgical spinal decompression, particularly when many other well investigated, less expensive alternatives are available" ¹⁴. This critique encapsulates the core ethical and clinical dilemma: the promotion of an expensive therapy for which superiority over cheaper alternatives has not been established.

The marketing of spinal decompression has historically sought to differentiate the treatment from conventional traction by promoting claims of unique biomechanical effects, such as the ability of computerized logarithmic pull patterns to bypass the body's natural muscle-guarding reflex ⁷⁴. Promoters argue this allows for the creation of significant negative intradiscal pressure, a mechanism first proposed by VAX-D inventor Allan Dyer, MD ⁵. While one 1994 study did measure negative pressure during traction ⁶, the clinical superiority derived from these purported mechanisms has not been consistently demonstrated in high-quality trials. A 2006 systematic review by Macario and Pergolizzi found the efficacy of motorized traction for chronic discogenic low back pain to be "unproven," citing a small number of low-quality studies ¹¹. The same review noted a stark difference between advertised success rates of 77% to 86%, derived from non-randomized studies without control groups, and the results from six of seven randomized studies that reported no significant difference in outcomes ¹⁰.

This lack of demonstrated superiority raises ethical questions about informed consent and the marketing of a costly intervention. High-quality randomized controlled trials have failed to support claims of a unique benefit. For instance, a 2009 trial by Schimmel et al. found no significant difference in pain or disability at the one-year follow-up between patients receiving a form of decompression therapy and those who received a sham traction treatment along with standard physiotherapy ¹³. Another randomized trial in 2017 by Demirel et al. found that while adding mechanical traction to a physiotherapy program was beneficial, there was no statistically significant difference in outcomes between the group receiving spinal decompression and the group receiving conventional motorized traction, a much less expensive modality ¹⁶. The promotion of an expensive therapy based on unsubstantiated claims of technological superiority, when its results are not demonstrably better than cheaper alternatives, remains the central limitation and point of contention for spinal decompression within the chiropractic and wider medical community.

Sources

1. Walter I. Wardwell, Chiropractic (1992) - https://openlibrary.org/works/OL4280776W

2. Russell W. Gibbons, Chiropractic history (1977) - https://openlibrary.org/works/OL5541722W

3. Ralph W. Stephenson, Chiropractic textbook (1927) - https://openlibrary.org/works/OL11214447W

4. Marketing for 'spinal decompression' in the 1990s and 2000s sought to differentiate it from older, less effective forms of traction by claiming the new computerized tables could bypass the body's muscle-guarding reflex, a claim not substantiated by high-quality evidence. - https://chiromt.biomedcentral.com/articles/10.1186/1746-1340-15-7

5. Allan Dyer, MD, the inventor of the VAX-D device, proposed that it worked by creating a negative intradiscal pressure, or vacuum effect, within the disc to draw herniated material back into the disc and promote healing. - https://vaxd.com/what-is-vax-d/

6. In a 1994 study by Ramos and Martin, intradiscal pressure in the third lumbar disc was measured to decrease to between -100 and -160 mm Hg during the application of vertebral axial decompression. - https://thejns.org/view/journals/j-neurosurg/81/3/article-p350.xml

7. The DRX9000 claims to differ from conventional traction by using a servo motor to apply a "logarithmic curve" pull pattern, which is purported to bypass the body's muscle guarding reflex to achieve negative intradiscal pressure. - https://www.thediscdocs.com/drx9000-spinal-decompression/

8. The Axiom DRX9000 was cleared under FDA 510(k) number K060735 as a Class II powered traction device. - https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K060735

9. The DRX9000 was cleared by the FDA via 510(k) premarket notification (K060735) as a Class II medical device with the indication for use being "relief of pain and symptoms associated with herniated discs, bulging/protruding discs, degenerative disc disease, posterior facet syndrome, and sciatica." - https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K060735

10. A 2006 systematic review by Macario and Pergolizzi found that six of seven randomized studies reported no difference in outcomes with motorized decompression, contrasting with advertised success rates of 77% to 86% found in three non-randomized studies that lacked a control group. - https://pubmed.ncbi.nlm.nih.gov/17147594/

11. A 2006 systematic review by Macario and Pergolizzi, reviewing the evidence for motorized traction for chronic discogenic low back pain, concluded that its efficacy remained "unproven" as the literature consisted of a small number of low-quality studies. - https://www.ncbi.nlm.nih.gov/pubmed/17147594

12. Joseph C. Keating, Chiropractic history: a primer (2004) - https://openlibrary.org/works/OL2025412W

13. Schimmel et al., 2009 - https://link.springer.com/article/10.1007/s00586-009-1011-3

14. In a 2007 critical review, Dwain M. Daniel, DC, concluded that "Only limited evidence is available to warrant the routine use of non-surgical spinal decompression, particularly when many other well investigated, less expensive alternatives are available." - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1887522/

15. The out-of-pocket cost for a course of 20 DRX9000 sessions is often quoted in the range of $2,000 to $5,000, as it is typically not covered by insurance. - https://www.reddit.com/r/Chiropractic/comments/ws86p6/drx9000_spinal_decompression_therapy_is_5k/

16. A 2017 study by Demirel et al. found that while both motorized decompression and conventional traction added to physiotherapy were more effective than physiotherapy alone, there was no statistically significant difference in outcomes between the spinal decompression and conventional motorized tracti - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300824/

17. Choi J, Lee S, Hwangbo G, 2015 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339166/

18. The 2020 NASS evidence-based clinical guidelines for multidisciplinary spine care for non-specific low back pain do not include a recommendation for or against motorized spinal decompression, as the treatment is not mentioned. - https://www.spine.org/Portals/0/assets/downloads/ResearchClinicalCare/Guidelines/LowBackPain.pdf

19. In a 2009 randomized controlled trial by Schimmel et al., there was no significant difference in outcomes at the one-year follow-up between patients receiving Intervertebral Differential Dynamics (IDD) therapy (a form of decompression) and those receiving a sham treatment. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899423/

20. The 2010 study by Apfel et al. was a retrospective cohort study, not a randomized controlled trial, and it found that patients' mean Oswestry Disability Index (ODI) scores improved significantly from baseline after treatment. - https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/1471-2474-11-155